|
|
J S Gill, A J Windebank
J Clin Invest. 1998;
101(12):2842
doi:10.1172/JCI1130
Abstract |
Full text
| PDF

P
latinum compounds induce apoptosis in malignant cells and are used extensively in the treatment of cancer. Total dose is limited by development of a sensory neuropathy. We now demonstrate that when rats are administered cisplatin (2 mg/kg i.p. for 5 d), primary sensory neurons in the dorsal root ganglion die by apoptosis. This was reproduced by exposure of dorsal root ganglion neurons and PC12 cells to cisplatin (3 microg/ml) in vitro. Apoptosis was confirmed by electron microscopy, DNA laddering, and inhibition by the caspase inhibitor z-VAD.fmk (100 microM). Cell death in vitro was preceded by upregulation of cyclin D1, cdk4, and increased phosphorylation of retinoblastoma protein; all are indicators of cell cycle advancement. The level of p16(INK4a), an endogenous inhibitor of the cyclin D1/cdk4 complex decreased. Exposure of PC12 cells and dorsal root ganglion neurons to increased levels of nerve growth factor (100 ng/ ml) prevented both apoptosis and upregulation of the cell cycle markers. Cancer cells without nerve growth factor receptors (gp140TrkA) were not protected by the neurotrophin. This indicated that cisplatin may kill cancer cells and neurons by a similar mechanism. In postmitotic neurons, this involves an attempt to re-enter the cell cycle resulting in apoptosis which is specifically prevented by nerve growth factor.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(63)
| Title and authors |
Publication |
Year |
DNA Repair in Cancer Therapy
Djane Braz Duarte, Michael R. Vasko
|
DNA Repair in Cancer Therapy
|
2012 |
The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum
Silvia Cerri, Valeria M. Piccolini, Giada Santin, Maria G. Bottone, Sandra A. De Pascali, Danilo Migoni, Paolo Iadarola, Francesco P. Fanizzi, Graziella Bernocchi
|
Neurotoxicology and Teratology
|
2011 |
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou, Jordi Bruna, Paola Marmiroli, Guido Cavaletti
|
Critical Reviews in Oncology/Hematology
|
2011 |
Les syndromes neurologiques paranéoplasiques
A. Didelot, J. Honnorat
|
La Revue de Médecine Interne
|
2011 |
Toxic neuropathy :
Hadi Manji
|
Current Opinion in Neurology
|
2011 |
Regulation of the latency–reactivation cycle by products encoded by the bovine herpesvirus 1 (BHV-1) latency-related gene
Clinton Jones, Leticia Frizzo Silva, Devis Sinani
|
J. Neurovirol.
|
2011 |
Pharmaceutical Sciences Encyclopedia
Carl D. Davis, Umesh M. Hanumegowda
|
Pharmaceutical Sciences Encyclopedia
|
2010 |
Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies
Gerardo Gutiérrez-Gutiérrez, María Sereno, Ambrosio Miralles, Enrique Casado-Sáenz, Eduardo Gutiérrez-Rivas
|
Clin Transl Oncol
|
2010 |
Different effects of erythropoietin in cisplatin- and docetaxel-induced neurotoxicity: An in vitro study
Daniele Maggioni, Gabriella Nicolini, Alessia Chiorazzi, Cristina Meregalli, Guido Cavaletti, Giovanni Tredici
|
J. Neurosci. Res.
|
2010 |
Role of Erythropoeitin in Prevention of Chemotherapy-induced Peripheral Neuropathy
M.D. Lobna Abdelaal K, M.D. Nadia Aziz Yassi
|
Pakistan J. of Biological Sciences
|
2010 |
|